gms | German Medical Science

29. Wissenschaftlicher Kongress der Deutschen Hochdruckliga

Deutsche Hochdruckliga e. V. DHL ® - Deutsche Hypertonie Gesellschaft Deutsches Kompetenzzentrum Bluthochdruck

23. bis 25.11.2005, Berlin

Reduced inflammation under candesartan treatment following transient focal ischemia in rats and in astrocyte primary culture

Meeting Abstract

  • K. Schmerbach - Charité Campus Mitte, Universitätsmedizin Berlin, CCR (Institut für Pharmakologie und Toxikologie), AG Prof. Unger, Berlin
  • M. Krikov - Charité Campus Mitte, Universitätsmedizin Berlin, CCR (Institut für Pharmakologie und Toxikologie), AG Prof. Unger, Berlin
  • S. Müller - Charité Campus Mitte, Universitätsmedizin Berlin, CCR (Institut für Pharmakologie und Toxikologie), AG Prof. Unger, Berlin
  • A. Villringer - Charité Campus Mitte, Universitätsmedizin Berlin, CCR (Institut für Pharmakologie und Toxikologie), AG Prof. Unger, Berlin
  • T. Unger - Charité Campus Mitte, Universitätsmedizin Berlin, CCR (Institut für Pharmakologie und Toxikologie), AG Prof. Unger, Berlin
  • C. Thöne-Reineke - Charité Campus Mitte, Universitätsmedizin Berlin, CCR (Institut für Pharmakologie und Toxikologie), AG Prof. Unger, Berlin
  • C. Neumann - Charité Campus Mitte, Universitätsmedizin Berlin, CCR (Institut für Pharmakologie und Toxikologie), AG Prof. Unger, Berlin
  • J. Schefe - Charité Campus Mitte, Universitätsmedizin Berlin, CCR (Institut für Pharmakologie und Toxikologie), AG Prof. Unger, Berlin

Hypertonie 2005. 29. Wissenschaftlicher Kongress der Deutschen Hochdruckliga. Berlin, 23.-25.11.2005. Düsseldorf, Köln: German Medical Science; 2006. Doc05hochP57

The electronic version of this article is the complete one and can be found online at: http://www.egms.de/en/meetings/hoch2005/05hoch057.shtml

Published: August 8, 2006

© 2006 Schmerbach et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

In recent studies, the AT1 receptor blocker (ARB), candesartan, was shown to reduce infarct size and improve neurological outcome after stroke. Since candesartan also exerts anti-inflammatory actions and since stroke is associated with an inflammatory response, we hypothesized that candesartan ameliorates ischemia-induced brain injury by an anti-inflammatory action.

Normotensive wistar rats were pretreated (p.o.; twice daily) for 5 days with 0,1 mg/kg candesartan or vehicle (0,9% NaCl). Middle cerebral artery occlusion (MCAO) was performed for 90 min with reperfusion. Infarct volume was measured by MRI 48h after ischemia followed by tissue asservation.

Candesartan significantly (p<0.05) improved neurological outcome (Garcia-scale) 24 and 48 h after stroke and reduced infarct volume by about 40% (p<0.05) compared to vehicle. Quantitative real-time PCR showed significant (p<0.05-0.001) reduction of inflammatory marker genes in candesartan-treated vs. vehicle-treated rats: TNF-alpha: -75%; CXCL-1: -60%; NF-kappaB: -18%.

For in vitro studies, a primary cell culture of neonatal astrocytes were prepared from neonatal cortex of Wistar rats (1-3 days postpartum) and kept for 10-14 days in culture. Cells were pretreated with 10-6 M candesartan or with vehicle for 24 h, stimulated with 500 ng/ml LPS for 2 h and additionally for 0,5; 2 and 24 h with Angiotensin II 10-8M. Real-time PCR showed a significant (50%) reduction of the inflammatory marker gene CXCL-1 under candesartan pretreatment vs. vehicle.

The results of our in vivo and in vitro studies identify anti-inflammtory mechanisms of candesartan which may contribute to the known beneficial effects of this ARB in cerebral ischemia.